… Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …

… transcription factor translocation and DNA transcription via … via cell surface receptors for
growth factors (GFs). This pathway is particularly important for EGF and fibroblast growth factor (…

… Identification of variable epidermal growth factor receptor (EGFR) gene mutations in non-small
cell lung cancer (NSCLC) is important for the selection of appropriate targeted therapies. …

… In the current review, we propose to illustrate the role of EGFR group of growth factors in lung
cancer progression and metastasis. We will particularly emphasize upon the impact of well-…

… Major advances with the development of epidermal growth factor receptor tyrosine kinase
inhibitors and immune check-point inhibitors have ushered in a new era in lung cancer therapy…

… type of lung cancer is non‐small cell lung cancer (NSCLC). … kind of cancer known as epidermal
growth factor receptor … in the cancer cells to the genes controlling tumour growth. In this …

… Vascular endothelial growth factor (VEGF) in lung cancer is considered an attractive
target for therapy due to the role this pathway plays in lung cancer growth and progression [63]. …

… outcomes of treatments in different groups of patients with advanced epidermal growth factor
receptor (egfr) mutated non-small cell lung cancer (nsclc). (a) comparisons on progression …

… and its impact on lung cancer progression. We found that HGF production … lung fibroblasts
was stimulated by lung cancer cells and that HGF promoted the survival of lung cancer cells. …

… to have a critical role in tumor angiogenesis. In the present study, the … growth factor (VEGF)
was investigated in lung cancer cell lines and non‑small‑cell lung cancer (NSCLC) tumor …